Literature DB >> 21450755

GnRH agonist for triggering of final oocyte maturation: time for a change of practice?

P Humaidan1, S Kol, E G Papanikolaou.   

Abstract

BACKGROUND: GnRH agonist (GnRHa) triggering has been shown to significantly reduce the occurrence of ovarian hyperstimulation syndrome (OHSS) compared with hCG triggering; however, initially a poor reproductive outcome was reported after GnRHa triggering, due to an apparently uncorrectable luteal phase deficiency. Therefore, the challenge has been to rescue the luteal phase. Studies now report a luteal phase rescue, with a reproductive outcome comparable to that seen after hCG triggering.
METHODS: This narrative review is based on expert presentations and subsequent group discussions supplemented with publications from literature searches and the authors' knowledge. Moreover, randomized controlled trials (RCTs) were identified and analysed either in fresh IVF cycles with embryo transfer (ET), oocyte donation cycles or cycles without ET; risk differences were calculated regarding pregnancy rate and OHSS rate.
RESULTS: In fresh IVF cycles with ET (9 RCTs) no OHSS was reported after GnRHa triggering [0% incidence in the GnRHa group: risk difference 5% (with 95% CI: -0.07 to 0.02)]. Importantly, the delivery rate improved significantly after modified luteal support [6% risk difference in favour of the HCG group (95% CI: -0.14 to 0.2)] when compared with initial studies with conventional luteal support [18% risk difference (95% CI: -0.36 to 0.01)]. In oocyte donation cycles (4 RCTs) the OHSS incidence is 0% [10% risk difference (95% CI: 0.02-0.40)].
CONCLUSIONS: GnRHa triggering is a valid alternative to hCG triggering, resulting in an elimination of OHSS. After modified luteal support there is now a non-significant difference of 6% in delivery rate in favour of hCG triggering.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21450755     DOI: 10.1093/humupd/dmr008

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  78 in total

1.  GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.

Authors:  Yannis Prapas; Konstantinos Ravanos; Stamatios Petousis; Yannis Panagiotidis; Achilleas Papatheodorou; Chrysoula Margioula-Siarkou; Assunta Iuliano; Giuseppe Gullo; Nikos Prapas
Journal:  J Assist Reprod Genet       Date:  2017-08-03       Impact factor: 3.412

2.  Empty follicle syndrome after GnRHa triggering versus hCG triggering in COS.

Authors:  Juan C Castillo; Juan Garcia-Velasco; Peter Humaidan
Journal:  J Assist Reprod Genet       Date:  2012-01-12       Impact factor: 3.412

3.  A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.

Authors:  Yanett Anaya; Douglas A Mata; Joseph Letourneau; Hakan Cakmak; Marcelle I Cedars; Mitchell P Rosen
Journal:  J Assist Reprod Genet       Date:  2017-10-30       Impact factor: 3.412

4.  Effect of GnRHa ovulation trigger dose on follicular fluid characteristics and granulosa cell gene expression profiles.

Authors:  Thi Ngoc Lan Vuong; M T Ho; T Q Ha; M Brehm Jensen; C Yding Andersen; P Humaidan
Journal:  J Assist Reprod Genet       Date:  2017-02-14       Impact factor: 3.412

5.  Ovarian biomarkers predict controlled ovarian stimulation for in vitro fertilisation treatment in Singapore.

Authors:  Ryan Wai Kheong Lee; Lay Wai Khin; Marianne Sybille Hendricks; Heng Hao Tan; Sadhana Nadarajah; Nancy Wen Sim Tee; Seong-Feei Loh; Bee Choo Tai; Jerry Ky Chan
Journal:  Singapore Med J       Date:  2020-09       Impact factor: 1.858

Review 6.  Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.

Authors:  Ali Abbara; Sophie A Clarke; Waljit S Dhillo
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

7.  Micro-dose hCG as luteal phase support without exogenous progesterone administration: mathematical modelling of the hCG concentration in circulation and initial clinical experience.

Authors:  C Yding Andersen; R Fischer; V Giorgione; Thomas W Kelsey
Journal:  J Assist Reprod Genet       Date:  2016-07-22       Impact factor: 3.412

8.  GnRH triggering may improve euploidy and live birth rate in hyper-responders: a retrospective cohort study.

Authors:  Justin Tan; Chen Jing; Lisa Zhang; Jasmine Lo; Arohumam Kan; Gary Nakhuda
Journal:  J Assist Reprod Genet       Date:  2020-06-13       Impact factor: 3.412

9.  GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.

Authors:  Kathleen E O'Neill; Suneeta Senapati; Ivy Maina; Clarisa Gracia; Anuja Dokras
Journal:  J Assist Reprod Genet       Date:  2016-06-27       Impact factor: 3.412

10.  A matched propensity score study of embryo morphokinetics following gonadotropin-releasing hormone agonist versus human chorionic gonadotropin trigger.

Authors:  Galia Oron; Onit Sapir; Avital Wertheimer; Yoel Shufaro; Roni Bar-Gil; Tamar Margalit; Ekaterina Shlush; Avi Ben-Haroush
Journal:  J Assist Reprod Genet       Date:  2020-09-27       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.